IP Library Granted Patent US 8,501,233
Granted Patent B2
US 8,501,233 · App. 12/530,852 · Granted Aug 6, 2013

Compositions and methods for treating cancer

Inventors: David Loren Carroll (Winston-Salem, NC); John H. Stewart, IV (Clemmons, NC); Nicole H. Levi (Winston-Salem, NC)
Assignees: Wake Forest University; Wake Forest University Health Sciences
A61K41/0052A61K9/0092A61K9/14A61K9/51A61N1/406Y10S977/742Y10S977/743Y10S977/752Y10S977/906Y10S977/911
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,501,233
App. No.
12/530,852
Granted
Aug 6, 2013
Kind
B2
Abstract

The present invention relates to compositions and methods for treating cancer and, in particular, to composition and methods comprising nanostructures. In one embodiment, the present invention provides a composition comprising a mixture, the mixture comprising at least one nanoparticle and at least one chemotherapeutic.

Claims (35)

1. A method of treating cancerous tissue comprising:

(a) providing a composition comprising a plurality of nanoparticles and at least one chemotherapeutic agent;

(b) disposing the composition in contact with cancerous tissue, and

(c) accelerating the uptake of the at least one chemotherapeutic agent by the cancerous tissue by irradiating the plurality of nanoparticles with electromagnetic radiation,

wherein irradiating the plurality of nanoparticles heats the cancerous tissue to a temperature of at least about 39° C. in a time period of less than 10 seconds.

2. The method of claim 1 , wherein the cancerous tissue is heated to a temperature ranging from about 39° C. to about 42° C.

3. The method of claim 1 , wherein the plurality of nanoparticles comprises carbon nanotubes.

4. The method of claim 3 , wherein carbon nanotubes comprise multi-walled carbon nanotubes.

5. The method of claim 3 , wherein the carbon nanotubes have a length ranging from about 500 nm to about 2 μm.

6. The method of claim 1 , wherein the at least one chemotherapeutic agent comprises oxaliplatin or Mitomycin C.

7. The method of claim 3 , wherein the carbon nanotubes are present in the composition at a concentration ranging from about 1 μg/ml to about 100 μg/ml.

8. The method of claim 1 , wherein the at least one chemotherapeutic agent is present in the composition at a concentration ranging from about 1 μM to about 300μM.

9. The method of claim 3 , wherein the at least one chemotherapeutic agent is at least partially disposed within the carbon nanotubes.

10. The method of claim 1 , wherein disposing the composition in contact with cancerous tissue comprises applying the composition locally to the cancerous tissue.

11. The method of claim 10 , further comprising repeating steps (b) and (c) at a plurality of localized areas of the cancerous tissue.

12. The method of claim 11 , wherein the plurality of localized areas are in the peritoneal cavity.

13. The method of claim 1 , wherein the electromagnetic radiation comprises ultra-violet, visible, infrared radiation or combinations thereof.

14. The method of claim 1 , wherein the cancerous tissue comprises colorectal cancerous tissue, bladder cancerous tissue, breast cancerous tissue, endometrial cancerous tissue, kidney cancerous tissue, lung cancerous tissue, leukemia, melanoma cancerous tissue, pancreatic cancerous tissue, prostate cancerous tissue, thyroid cancerous tissue, or combinations thereof.

15. The method of claim 1 , wherein the uptake of the at least one chemotherapeutic agent by the cancerous tissue subsequent to irradiation of the plurality of nanoparticles for the 10 seconds is substantially equivalent to the uptake of the at least one chemotherapeutic agent by the cancerous tissue subsequent to heating the cancerous tissue at a temperature of 42° C. for two hours in the presence of the at least one chemotherapeutic agent alone.

16. The method of claim 1 , wherein irradiating comprises providing a surgeon with a hand-held laser wherein the surgeon positions the laser proximate the cancerous tissue.

17. The method of claim 1 , wherein the at least one chemotherapeutic agent is not disposed in a nanoparticle.

18. A method of treating cancerous tissue comprising:

(a) providing a composition comprising a plurality of nanoparticles and at least one chemotherapeutic agent;

(b) disposing the composition in contact with cancerous tissue, and

(c) accelerating the uptake of the at least one chemotherapeutic agent by the cancerous tissue by irradiating the plurality of nanoparticles with electromagnetic radiation,

wherein the plurality of nanoparticles comprises carbon nanotubes and irradiating the plurality of nanoparticles heats the cancerous tissue to a temperature of at least about 42° C. in a time period of less than 30 seconds.

19. The method of claim 18 , wherein the carbon nanotubes comprise multi-walled carbon nanotubes.

20. The method of claim 18 , wherein the carbon nanotubes have a length ranging from about 500 nm to about 2 μm.

21. The method of claim 18 , wherein the carbon nanotubes are present in the composition at a concentration ranging from about 1 μg/ml to about 100 μg/ml.

22. The method of claim 18 , wherein the at least one chemotherapeutic agent comprises oxaliplatin or Mitomycin C.

23. The method of claim 18 , wherein the at least one chemotherapeutic agent is not disposed in a nanoparticle.

24. The method of claim 18 , wherein the at least one chemotherapeutic agent is at least partially disposed within the carbon nanotubes.

25. The method of claim 24 , wherein at least one carbon nanotube is capped with a polymeric material.

26. The method of claim 25 , wherein the polymeric material comprises alginate, poly(lactic)-co-glycolic acid, polylactic acid, poly(decandiol) citrate, or combinations thereof.

27. The method of claim 18 , wherein the cancerous tissue comprises colorectal cancerous tissue, bladder cancerous tissue, breast cancerous tissue, endometrial cancerous tissue, kidney cancerous tissue, lung cancerous tissue, leukemia, melanoma cancerous tissue, pancreatic cancerous tissue, prostate cancerous tissue, thyroid cancerous tissue, or combinations thereof.

Continuity (2)
Provisional Application 60906746 · Mar 13, 2007
Related Publication 20100209479A1 · Aug 19, 2010